Does IGF-1 LR3 really work?
IGF-1 LR3 has biological activity in laboratory research. That is not the same as clinical proof that it safely improves muscle growth, recovery or performance in people.
IGF-1 LR3 is not currently offered through AnthologyRX. This guide remains available for general information.
Is LR3 the same as INCRELEX?
No. IGF-1 LR3 is a modified analogue, distinct from mecasermin, the ingredient in INCRELEX. INCRELEX is approved for growth failure in children aged two and older with severe primary IGF-1 deficiency, or with growth-hormone gene deletion and neutralizing antibodies to growth hormone. That approval does not establish approval, benefit or safety for this compounded LR3 injection or for adult recovery and performance.
Read: INCRELEX prescribing information; FDA: Compounding questions and answers.
What the foundational research tells us
The cited analogue research examines how modified IGF-1 interacts with binding proteins and laboratory systems. It does not test a muscle-building prescription program in patients.
A separate clearance study gave radiolabeled IGF-1 and LR3 intravenously to pregnant and virgin rats. LR3 cleared from blood faster than IGF-1 in that experiment. It does not establish LR3’s half-life or a dosing schedule in people.
Read: Francis et al. IGF-1 analogues and binding proteins; Bastian et al. IGF-I and LR3IGF-I clearance in rats.
Is it the next step after CJC-1295/ipamorelin?
The sources here do not establish a treatment ladder in which LR3 is the appropriate escalation after another peptide. A stronger mechanistic effect is not the same as a better clinical outcome. Those decisions need evidence for the actual problem and preparation.
Before considering treatment
Ask what diagnosis or measurable outcome is being addressed, which human studies support it and how the proposed plan compares with established care. Make sure the full safety and follow-up plan is clear rather than inferring safety from a product’s research history.
Sources
- Francis et al. IGF-1 analogues and binding proteins
Journal of Molecular Endocrinology, 1992. Laboratory analogue research, not a muscle-building clinical trial.
- Bastian et al. IGF-I and LR3IGF-I clearance in rats
Journal of Endocrinology, 1993. Radiolabeled peptides administered intravenously to pregnant and virgin rats; not human pharmacokinetics.
- INCRELEX prescribing information
DailyMed. Mecasermin for specified pediatric growth-failure indications; a different molecule from IGF-1 LR3.
- FDA: Compounding questions and answers
The distinction between compounded medications and FDA-approved drug products.
